TB-500: A Research Overview of the Thymosin Beta-4 Peptide

What is TB-500?

TB-500 is a synthetic research peptide that has been widely studied in the context of tissue repair and regeneration. To understand it properly, it helps to start with one point that is often blurred in online descriptions: TB-500 is closely related to a naturally occurring protein called thymosin beta-4, and almost all of the published scientific literature is on that parent molecule rather than on the commercial name "TB-500."

This article summarises that published literature for researchers. TB-500 is supplied strictly as a reagent for in vitro laboratory research. It is not approved for human or veterinary use, and nothing here describes, recommends, or implies any such use.

TB-500 and thymosin beta-4

Thymosin beta-4, often written as Tbeta4 or Tβ4, is a small, naturally occurring peptide found inside cells and in body fluids. According to PubMed, it belongs to the beta-thymosin family and its best-characterised molecular function is binding to actin, one of the structural proteins of the cell DOI.

TB-500 is the name under which a synthetic peptide corresponding to the active region of thymosin beta-4 is studied and supplied. When the research literature refers to thymosin beta-4, it is describing the biology that underpins interest in TB-500. We use both terms in this article accordingly.

Mechanisms studied in research

Actin binding and cell migration

The foundational molecular activity of thymosin beta-4 is its interaction with actin. According to PubMed, this actin-binding role is central to how the peptide is thought to influence cell movement, and reviews describe it promoting cell migration in the context of tissue repair DOI.

Angiogenesis and anti-inflammatory activity

A consistent theme in the literature is a combination of angiogenic and anti-inflammatory properties. According to PubMed, thymosin beta-4 is described as a naturally occurring regenerative protein with angiogenic and anti-inflammatory activity, present at high levels in the platelets that aggregate at a wound site, and reported to increase the rate of dermal healing in preclinical animal models including diabetic and aged animals, and in burn models DOI.

The research landscape

The thymosin beta-4 literature is broader than that of many research peptides, and it is worth being precise about what kind of evidence exists.

Much of it is preclinical, in animal models. According to PubMed, a 2006 review examined thymosin beta-4 in cardiac healing after myocardial infarction, describing experimental findings in animal models while stating plainly that there were no clinical trial data supporting its use in patients for that purpose DOI.

However, unlike some peptides, thymosin beta-4 has also progressed into early human studies in certain areas. According to PubMed, reviews report that it has been the subject of Phase 2 trials in wound contexts such as pressure ulcers, stasis ulcers and epidermolysis bullosa, and describe it as having been used in several clinical trials involving tissue repair and regeneration, with further trials discussed across eye, dermal, cardiac and neurological applications DOI, DOI.

The accurate summary is therefore a mix: an extensive preclinical foundation, some early-stage human trial activity in specific wound-healing contexts, and no approved therapeutic use.

Regulatory and research status

TB-500 and thymosin beta-4 have not been approved by the MHRA, the FDA, or other regulators as a medicine for general use. It is not a licensed treatment and not a supplement.

It is also worth noting for completeness that thymosin beta-4 is prohibited in sport by the World Anti-Doping Agency. In the United Kingdom, peptides of this kind are supplied for laboratory research use only, and Axiom supplies TB-500 strictly on that basis.

Relationship to BPC-157 and the KLOW blend

TB-500 is frequently discussed alongside BPC-157, as both have been studied in tissue-repair contexts, and the two appear together in research blends. Our KLOW blend, for example, combines GHK-Cu, BPC-157, TB-500 and KPV. The science of each component is distinct, and our individual overviews (see the BPC-157 research overview) cover them separately.

Handling in the research setting

Like other peptides in this category, TB-500 is supplied as a lyophilised powder, reconstituted for laboratory use, and characterised by purity and identity against a certificate of analysis. Standard peptide-handling practice applies: low-temperature storage of the powder, careful reconstitution, and minimising freeze-thaw cycles of any reconstituted solution. Our general handling guidance covers this in detail.

Summary

TB-500 is a synthetic peptide corresponding to thymosin beta-4, a naturally occurring actin-binding protein with reported angiogenic and anti-inflammatory activity. Its research literature spans an extensive preclinical base and some early human trials in specific wound-healing settings, but it has no approved therapeutic use. For researchers, it is a well-studied and mechanistically interesting compound, and one that is handled, and discussed, strictly within a research-use-only context.